Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Amsacrine→

Amsacrine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
51264-14-3
Molecular formula
C21H19N3O3S
Molecular weight
393.5 g/mol
Drug class
Antineoplastic aminoacridine derivative
Mechanism of action
Its mechanism is incompletely defined; available pharmacology describes DNA intercalation and inhibition of topoisomerase II, leading to DNA damage and tumour-cell death.
Indications / reported uses
  • Acute leukaemia (reported clinical-use context; current authorisation and use are jurisdiction- and product-specific)

Sources: NCI Drug Dictionary

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Amsacrine Environmental Risk Assessment (ERA) (the Amsacrine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.